Translational experimental research in gynaecological oncology

Matthias B. StopeDepartment of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, GermanyCorrespondence[email protected]

Damian J. RalserDepartment of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany

Eva K. EggerDepartment of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany

Alexander MusteaDepartment of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany

References

Hofmann C, Stühmer T, Schmiedl N, Wetzker R, Mottok A, Rosenwald A, et al. 2014. PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. British Journal of Haematology 166:529–539.
PubMed Web of Science ®Google Scholar
Jain S, Santa-Maria CA, Rademaker A, Giles FJ, Cristofanilli M, Gradishar WJ. 2017. Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. Journal of Clinical Oncology 35:1026.
Web of Science ®Google Scholar
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73.
PubMed Web of Science ®Google Scholar
Pilie PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. 2019. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clinical Cancer Research 25:3759–3771.
PubMed Web of Science ®Google Scholar
Rubio DM, Primack BA, Switzer GE, Bryce CL, Seltzer DL, Kapoor WN. 2011. A comprehensive career-success model for physician-scientists. Academic Medicine 86:1571–1576.
PubMed Web of Science ®Google Scholar
Shah PD, Chandarlapaty S, Dickler MN, Ulaner G, Zamora SJ, Iasonos VSA, et al. 2015. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). Journal of Clinical Oncology 33:590.
Web of Science ®Google Scholar
Stope MB. 2020. Plasma oncology – physical plasma as innovative tumor therapy. Journal of Cancer Biology 1:53–56.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Translational experimental research in gynaecological oncology

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Translational experimental research in gynaecological oncology

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date